Search results for "vascular invasion"

showing 10 items of 14 documents

Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines a…

2021

Summary Purpose In the ACOSOG Z0011 trial, patients with primary breast cancer and 1–2 tumor-involved sentinel lymph nodes (SLNs) undergoing breast-conserving surgery had no oncological outcome benefit after axillary lymph node dissection (ALND), despite a relevant rate of non-SLN metastases of 27%. According to the St Gallen expert consensus, and NCCN and ASCO clinical guidelines, ALND may be avoided in patients who meet all ACOSOG Z0011 inclusion criteria. This recommendation can also be extended to patients undergoing mastectomy, with 1 or 2 positive SLNs and an indication for chest wall radiation, in whom axillary radiotherapy can be proposed as an alternative to completion ALND. The ai…

AdultCancer Researchmedicine.medical_specialtyLymphovascular invasionmedicine.medical_treatmentSentinel lymph nodeBreast NeoplasmsCohort StudiesBreast cancermedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyMastectomySocieties MedicalAgedAged 80 and overbusiness.industryAxillary Lymph Node DissectionCancerHematologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseUnited StatesOncologyLymphatic MetastasisAxillaPractice Guidelines as TopicLymph Node ExcisionFemaleGuideline AdherenceRadiologySentinel Lymph NodebusinessMastectomyBulletin du Cancer
researchProduct

High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression

2013

Tryptase(+) mast cells (MCs), abundant in the invasive front of tumours, contribute to tissue remodelling. Indeed, protease-activated receptor- 2 (PAR-2) activation by MC-tryptase is considered an oncogenic event in colorectal cancer (CRC). Recently, we have suggested NHERF1 as a potential new marker in CRC. In this study, we aimed to determine the distribution of tryptase(+) MCs and PAR-2 and to examine the relationship between PAR-2 and NHERF1, investigating their reputed usefulness as tumour markers. We studied a cohort of 115 CRC specimens including primary cancer (C) and adjacent normal mucosa (NM) by immunohistochemical double staining, analyzing the protein expression of MC-tryptase,…

AdultMaleCytoplasmPathologymedicine.medical_specialtySodium-Hydrogen ExchangersColorectal cancerLymphovascular invasionSettore MED/06 - Oncologia MedicainvasivenesstryptasePAR-2Cell CountTryptaseModels BiologicalImmunophenotypingNHERF1Intestinal mucosamedicineHumansReceptor PAR-2Mast CellsIntestinal Mucosaprognostic factorProtease-activated receptor 2AgedAged 80 and overbiologyColorectal cancer PAR-2 mast cell tryptase NHERF1 prognostic factor invasiveness aggressivenessOriginal ArticlesCell BiologyaggressivenessMiddle AgedPhosphoproteinsPrognosismedicine.diseaseMast cellColorectal cancermedicine.anatomical_structurebiology.proteinMolecular MedicineImmunohistochemistryFemaleTryptasesmast cellColorectal Neoplasms
researchProduct

Correlation study of GAPDH, Bcl-2, and Bax protein immunoexpression in patients with colorectal adenocarcinoma.

2018

Introduction Colorectal cancer (CRC) is the third and second most commonly diagnosed cancer worldwide in males and females, respectively. Despite prominent progress in diagnosis and treatment, the recurrence rates are still high. A tumour hypoxic environment leads to an increase in glycolytic metabolism. The crucial intermediate component of glycolysis, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), could play a significant role in cancer progression. An increased level of GAPDH has been described in oncogene-induced transformation and anti-apoptotic function. In other studies, GAPDH has been involved in apoptosis induction. Aim We examined colorectal adenocarcinoma samples to assess the…

Colorectal cancerLymphovascular invasionlcsh:Medicinecolorectal cancer02 engineering and technology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineDownregulation and upregulationstomatognathic systemBcl-2 proteinsmedicineGlycolysisGlyceraldehyde 3-phosphate dehydrogenaseOriginal Paperbiologybusiness.industryhypoxialcsh:RGastroenterologyapoptosisCancerglycolysis021001 nanoscience & nanotechnologymedicine.diseasePrimary and secondary antibodiesApoptosisbiology.proteinCancer research0210 nano-technologybusinessPrzeglad gastroenterologiczny
researchProduct

VEGFR-2, HSP90 and GRP78/BiP expression and HCC recurrence after Liver Transplantation

2018

Introduction Liver transplantation (LT) for hepatocellular carcinoma (HCC) is a satisfactory therapeutic choice in patients with “early HCC” selected according to Milan criteria. However, the risk of HCC recurrence after LT is about 7-20% at five years and molecular markers which can predict recurrence are still lacking. We investigated in HCC samples and LC surrounding tissues the significance of VEGFR-2, HSP90, and GRP78/BiP expression in patients with HCC who underwent LT in a western transplantation center and their possible role as molecular markers of recurrence. Methods 42 patients (35 M, 7 F) with early HCC who underwent LT between 2012 and 2013 were enrolled. The tumor recurrence r…

GRP78/BiPVEGFR-2Liver transplantationHepatocellular carcinomaHSP90Microvascular invasion
researchProduct

The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper

2019

BACKGROUND AND PURPOSES: To describe current practice in the management of rectal cancer, to identify uncertainties that usually arise in the multidisciplinary team (MDT)'s discussions ('grey zones') and propose next generation studies which may provide answers to them. MATERIALS AND METHODS: A questionnaire on the areas of controversy in managing T2, T3 and T4 rectal cancer was drawn up and distributed to the Rectal-Assisi Think Tank Meeting (ATTM) Expert European Board. Less than 70% agreement on a treatment option was indicated as uncertainty and selected as a 'grey zone'. Topics with large disagreement were selected by the task force group for discussion at the Rectal-ATTM. RESULTS: The…

MaleBest practice guidelinesColorectal cancermedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEMedical Oncology030218 nuclear medicine & medical imagingCOLORECTAL-CANCER0302 clinical medicineADJUVANT CHEMOTHERAPYRectal cancerNeoadjuvant therapyRandomized Controlled Trials as TopicSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIARadiology Nuclear Medicine & Medical ImagingChemoradiotherapyCytoreduction Surgical ProceduresHematologyMiddle AgedOPEN-LABELTotal mesorectal excisionNeoadjuvant TherapyOncology030220 oncology & carcinogenesisFemaleLife Sciences & Biomedicinemedicine.medical_specialtyOrgan preservationLOCAL RECURRENCEAreas of uncertaintiesCOURSE PREOPERATIVE RADIOTHERAPYAreas of uncertainties; Best practice guidelines; Colorectal cancer; Organ preservation; Personalized medicine;03 medical and health sciencesLow rectal cancerRADIATION-THERAPYmedicineHumansRadiology Nuclear Medicine and imagingMedical physicsEXTRAMURAL VASCULAR INVASIONNeoplasm StagingScience & TechnologyRectal Neoplasmsbusiness.industryTask forceAreas of uncertainties; Best practice guidelines; Colorectal cancer; Organ preservation; Personalized medicineTOTAL MESORECTAL EXCISIONRANDOMIZED PHASE-IIINEOADJUVANT CHEMORADIOTHERAPYmedicine.diseaseColorectal cancerPersonalized medicineClinical trialRadiation therapyPersonalized medicinebusiness
researchProduct

The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, …

2005

Purpose The aims of the TP53 Colorectal Cancer (CRC) International Collaborative Study were to evaluate the possible associations between specific TP53 mutations and tumor site, and to evaluate the prognostic and predictive significance of these mutations in different site, stage, and treatment subgroups. Patients and Methods A total of 3,583 CRC patients from 25 different research groups in 17 countries were recruited to the study. Patients were divided into three groups according to site of the primary tumor. TP53 mutational analyses spanned exons 4 to 8. Results TP53 mutations were found in 34% of the proximal colon tumors and in 45% of the distal colon and rectal tumors. They were assoc…

MaleOncologyCancer Researchmedicine.medical_specialtyPathologyRECTAL-CARCINOMATumor suppressor geneColorectal cancerLymphovascular invasionMICROSATELLITE INSTABILITYCELL LUNG-CANCERDNA Mutational AnalysisALLELIC LOSSDUKES STAGE-BMOLECULAR MARKERSInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineGenetic Predisposition to DiseaseNeoplasm InvasivenessStage (cooking)neoplasmsSurvival rateAgedNeoplasm Stagingbusiness.industryCOLON-CANCERMicrosatellite instabilityZINC-BINDING DOMAINExonsMiddle AgedWILD-TYPE P53medicine.diseaseAdenocarcinoma MucinousPrimary tumorSurvival RateOncologyChemotherapy AdjuvantMutationAdenocarcinomaFemaleZINC-BINDING DOMAIN; CELL LUNG-CANCER; DUKES STAGE-B; WILD-TYPE P53; GENETIC PATHWAYS; COLON-CANCER; MICROSATELLITE INSTABILITY; MOLECULAR MARKERS; RECTAL-CARCINOMA; ALLELIC LOSSGENETIC PATHWAYSTumor Suppressor Protein p53Colorectal NeoplasmsbusinessFollow-Up Studies
researchProduct

Liver transplantation for hepatocellular carcinoma with intrahepatic lymphatic invasion: case reports.

2008

Multiple studies addressing liver transplantation (OLT) for hepatocellular carcinoma (HCC) have identified various prognostic determinants of tumor recurrence and decreased patient survival. However, little information is available on the impact of intrahepatic lymphatic invasion on tumor recurrence and survival after OLT for HCC. Intrahepatic lymphatic invasion was observed in 1.4% (n = 2) of liver explants with HCC in our series. Both recipients are alive without tumor recurrence at 16 and 39 months post-OLT, respectively. Intrahepatic lymphatic invasion may not be an absolute adverse prognostic factor in cases of HCC with no hilar lymph node involvement at the time of OLT.

MalePathologymedicine.medical_specialtyCarcinoma HepatocellularLymphovascular invasionmedicine.medical_treatmentLiver transplantationGastroenterologyMetastasisInternal medicinemedicineHumansNeoplasm InvasivenessLymph nodeTransplantationbusiness.industryLiver NeoplasmsCancerMiddle Agedmedicine.diseasedigestive system diseasesLiver Transplantationsurgical procedures operativeLymphatic systemmedicine.anatomical_structureTreatment OutcomeHepatocellular carcinomaSurgeryFemaleLiver cancerbusinessTransplantation proceedings
researchProduct

Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal V…

2014

Background: Approximately 10-20% of recurrences in patients treated with nephrectomy for renal cell carcinoma (RCC) develop beyond 5 yr after surgery (late recurrence). Objective: To determine features associated with late recurrence. Design, setting, and participants: A total of 5009 patients from a multicenter database comprising 13 107 RCC patients treated surgically had a minimum recurrence-free survival of 60 mo (median follow-up [FU]: 105 mo [range: 78-135]); at last FU, 4699 were disease free (median FU: 103 mo [range: 78-134]), and 310 patients (6.2%) experienced disease recurrence (median FU: 120 mo [range: 93-149]). Interventions: Patients underwent radical nephrectomy or nephron-…

MaleTime FactorsDatabases FactualLymphovascular invasionmedicine.medical_treatmentPredictive Value of Testcomputer.software_genreNephrectomyRisk modelDecision Support TechniqueRisk FactorsRetrospective StudieRenal cell carcinomaOdds Ratiolate recurrencenephrectomyMedicineMultivariate AnalysiFramingham Risk ScoreDatabaseKidney Neoplasmrenal carcinomaPrognostic parametersMiddle AgedNephrectomyKidney NeoplasmsTreatment OutcomeLymphatic MetastasisFemaleRadiologyNephron sparing surgeryPrognostic parameterHumanmedicine.medical_specialtyrenal cell carcinomarecurrenceLogistic ModelTime FactorUrologyReproducibility of ResultLate recurrencecancer-specific mortalityrisk scoreRisk AssessmentDisease-Free SurvivalDecision Support Techniquescancer-specific mortality; late recurrence; nephrectomy; prognostic parameters; renal cell carcinoma; risk scorePredictive Value of TestsLate RecurrenceHumansInternal validationCarcinoma Renal CellProportional Hazards ModelsRetrospective StudiesAgedNeoplasm StagingChi-Square Distributionbusiness.industryProportional hazards modelRisk Factorrenal cell carcinoma; recurrence; Cancer-specific mortality; Late recurrence; Nephrectomy; Prognostic parameters; Risk scoreCancer-specific mortalityReproducibility of ResultsLymphatic MetastasiRetrospective cohort studyOdds ratioprognostic parametersmedicine.diseaseConfidence intervalLogistic ModelsMultivariate AnalysisProportional Hazards ModelRisk scoreNeoplasm GradingNeoplasm Recurrence LocalbusinesscomputerCancer-specific mortality; Late recurrence; Nephrectomy; Prognostic parameters; Renal cell carcinoma; Risk score
researchProduct

Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison

2022

Objective: The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario. Background data: The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial. Methods: BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups. Results: Between 2008 and 2019, 478 patients…

NiacinamideCarcinoma HepatocellularHepatocellular carcinomahepatocellular carcinoma surgery sorafenib bclcPhenylurea CompoundsCarcinomaSettore MED/09 - MEDICINA INTERNALiver Neoplasmsadvanced HCCHepatocellularAntineoplastic Agentssystemic therapies.SorafenibBCLC CNOTreatment Outcomesystemic therapiesmacrovascular invasionHumansHepatectomySurgeryHepatectomy; Humans; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; Antineoplastic Agents; Carcinoma Hepatocellular; Liver NeoplasmsLiver surgeryNeoplasm StagingRetrospective Studies
researchProduct

Breast cancer subtypes can be determinant in the decision making process to avoid surgical axillary staging: A retrospective cohort study.

2015

Abstract Introduction The need for performing axillary lymph-node dissection in early breast cancer when the sentinel lymph node (SLN) is positive has been questioned in recent years. The purpose of this study was to identify a low-risk subgroup of early breast cancer patients in whom surgical axillary staging could be avoided, and to assess the probability of having a positive lymph-node (LN). Methods We evaluated the cohort of 612 consecutive women affected by early breast cancer. We considered age, tumor size, histological grade, vascular invasion, lymphatic invasion and cancer subtype (Luminal A, Luminal B HER-2+, Luminal B HER-2−, HER-2+, and Triple Negative) as variables for univariat…

OncologyAdultmedicine.medical_specialtyLymphovascular invasionReceptor ErbB-2Sentinel lymph nodeClinical Decision-Makingbreast cancer axillary surgery sentinel lymph node biopsy adjuvant treatment biological prognostic factors.Breast NeoplasmsTriple Negative Breast NeoplasmsCohort StudiesBreast cancerInternal medicineMedicineHumansNeoplasm InvasivenessSettore SECS-S/05 - Statistica SocialeLymph nodeAgedNeoplasm StagingRetrospective StudiesGynecologyAged 80 and overbusiness.industrySentinel Lymph Node BiopsyAge FactorsCancerRetrospective cohort studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseSettore MED/18 - Chirurgia GeneraleExact testmedicine.anatomical_structureLymphatic MetastasisAxillaLymph Node ExcisionSurgeryFemalebusinessInternational journal of surgery (London, England)
researchProduct